Skip to main content
Contact Us

Exports & Global Regulatory Affairs

Navigating CTD & ACTD Regulatory Dossiers for Pharmaceutical Exports to Emerging Markets

Published July 2026 • Updated September 2026 8 min read International Regulatory Affairs

For international pharmaceutical distributors and importers, registering generic medicines in emerging markets requires navigating complex regulatory frameworks. Harmonized dossier compilation in Common Technical Document (CTD) or ASEAN Common Technical Dossier (ACTD) format is the critical bridge connecting WHO-GMP manufacturing in Pakistan with timely market access worldwide.

Table of Contents

Export Regulatory Insight

Over 70% of dossier rejections or regulatory delays in importing countries result from incomplete Module 3 (Chemistry, Manufacturing, and Controls) documentation, unvalidated analytical test methods, or inadequate real-time stability data in Zone IV climatic conditions.

1. Comparing CTD and ACTD Formats

Depending on the importing territory, health ministries require registration submissions structured under one of two standardized guidelines:

Dossier Format ICH CTD (Common Technical Document) ACTD (ASEAN Common Technical Dossier)
Organization 5 Modules (1: Admin, 2: Summaries, 3: Quality, 4: Non-clinical, 5: Clinical). 4 Parts (I: Administrative, II: Quality, III: Non-clinical, IV: Clinical).
Target Regions GCC/Middle East, Central Asia (CIS), South Africa, Europe, Americas. ASEAN territories (Vietnam, Cambodia, Philippines, Myanmar), select African nations.
Generic Medicine Focus Module 4 & 5 often substituted with published literature and Bioequivalence (BE) data. Parts III & IV simplified for established generic molecules with proven clinical history.

2. Module 3 / Part II: The Quality (CMC) Dossier

The core of any generic drug registration application is the Quality or Chemistry, Manufacturing, and Controls (CMC) section. Star Laboratories' regulatory affairs team compiles comprehensive technical data covering:

  • Drug Substance (S Section): Nomenclature, structure, physicochemical characteristics, synthesis route summary, specification, analytical procedures, and retest period.
  • Drug Product (P Section): Pharmaceutical development, formulation components, overages, manufacturing process flow charts, critical process controls (CPCs), and packaging barrier specifications.
  • Analytical Method Validation: Full ICH Q2(R1) validation data confirming specificity, linearity, range, accuracy, precision, and robustness for chromatographic assays.

3. Stability Testing Protocols for Zone IVa & IVb

Developing nations across Asia and Africa present high ambient heat and humidity requiring rigorous stability compliance:

Drug dossiers must demonstrate real-time and accelerated stability stability in environmental test chambers adhering strictly to ICH Zone IVa ($30^\circ\text{C} \pm 2^\circ\text{C} / 65\% \pm 5\% \text{RH}$) or Zone IVb ($30^\circ\text{C} \pm 2^\circ\text{C} / 75\% \pm 5\% \text{RH}$). At Star Laboratories, batches are tested at 0, 3, 6, 9, 12, 18, 24, and 36 months to validate shelf-life claims.

4. WHO Certification Scheme & The CoPP

The Certificate of Pharmaceutical Product (CoPP) is an indispensable requirement for international health ministry submissions. Issued by DRAP in accordance with WHO guidelines, it validates three essential facts:

  1. 1

    Marketing Authorization Status

    Certifies that the specific drug formulation is actively registered and authorized for commercial distribution in Pakistan.

  2. 2

    Manufacturing Site cGMP Compliance

    Confirms that the manufacturing facility in Lahore undergoes routine statutory inspection and adheres to WHO-recommended Good Manufacturing Practices.

  3. 3

    Approved Labeling & Packaging

    Accompanies approved packaging artwork, summary of product characteristics (SmPC), and active formulation breakdown.

5. Star Laboratories' Export Dossier Support

With an established export presence in over 30 countries since 1962, Star Laboratories provides end-to-end regulatory support for overseas partners, including complete CTD/ACTD dossier compilation, bioequivalence study references, legal documentation (Apostille / Embassy Attestation), and Certificate of Free Sale (CFS).

Published by Star Laboratories Regulatory Affairs Directorate

Our regulatory team supports distributors across Central Asia, Africa, and the Middle East in securing rapid registration approvals for human and veterinary generic medicines.

6. Frequently Asked Questions (FAQ)

How long does it take Star Laboratories to prepare a full export CTD dossier?

For existing registered commercial formulations with complete stability data, a customized CTD or ACTD dossier is compiled and ready for dispatch within 3 to 4 weeks.

Does Star Laboratories assist with local embassy legalization of export documents?

Yes. We facilitate complete document authentication, including Ministry of Foreign Affairs (MOFA) attestation and target country embassy legalization in Islamabad for CoPPs, manufacturing licenses, and distribution agreements.

Expand Your Pharmaceutical Portfolio with Star Laboratories

Discover our export capabilities, registration assistance, and global distribution network.

View Export Markets Inquire About Dossier Availability